Literature DB >> 21441606

Melatonin in experimental seizures and epilepsy.

Monika Banach1, Elwira Gurdziel, Marian Jędrych, Kinga K Borowicz.   

Abstract

Although melatonin is approved only for the treatment of jet-lag syndrome and some types of insomnia, clinical data suggest that it is effective in the adjunctive therapy of osteoporosis, cataract, sepsis, neurodegenerative diseases, hypertension, and even cancer. Melatonin also modulates the electrical activity of neurons by reducing glutamatergic and enhancing GABA-ergic neurotransmission. The indoleamine may also be metabolized to kynurenic acid, an endogenous anticonvulsant. Finally, the hormone and its metabolites act as free radical scavengers and antioxidants. The vast majority of experimental data indicates anticonvulsant properties of the hormone. Melatonin inhibited audiogenic and electrical seizures, as well as reduced convulsions induced by pentetrazole, pilocarpine, L-cysteine and kainate. Only a few studies have shown direct or indirect proconvulsant effects of melatonin. For instance, melatonin enhanced low Mg2+-induced epileptiform activity in the hippocampus, whereas melatonin antagonists delayed the onset of pilocarpine-induced seizures. However, the relatively high doses of melatonin required to inhibit experimental seizures can induce some undesired effects (e.g., cognitive and motor impairment and decreased body temperature). In humans, melatonin may attenuate seizures, and it is most effective in the treatment of juvenile intractable epilepsy. Its additional benefits include improved physical, emotional, cognitive, and social functions. On the other hand, melatonin has been shown to induce electroencephalographic abnormalities in patients with temporal lobe epilepsy and increase seizure activity in neurologically disabled children. The hormone showed very low toxicity in clinical practice. The reported adverse effects (nightmares, hypotension, and sleep disorders) were rare and mild. However, more placebo-controlled, double-blind randomized clinical trials are needed to establish the usefulness of melatonin in the adjunctive treatment of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441606     DOI: 10.1016/s1734-1140(11)70393-0

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  19 in total

Review 1.  Chronobiology of limbic seizures: Potential mechanisms and prospects of chronotherapy for mesial temporal lobe epilepsy.

Authors:  Daniel Leite Góes Gitai; Tiago Gomes de Andrade; Ygor Daniel Ramos Dos Santos; Sahithi Attaluri; Ashok K Shetty
Journal:  Neurosci Biobehav Rev       Date:  2019-01-07       Impact factor: 8.989

2.  Melatonin Alleviates the Epilepsy-Associated Impairments in Hippocampal LTP and Spatial Learning Through Rescue of Surface GluR2 Expression at Hippocampal CA1 Synapses.

Authors:  Yue Ma; Xiaolong Sun; Juan Li; Ruihua Jia; Fang Yuan; Dong Wei; Wen Jiang
Journal:  Neurochem Res       Date:  2017-02-18       Impact factor: 3.996

3.  d-Leucine: Evaluation in an epilepsy model.

Authors:  Kylie Holden; Adam L Hartman
Journal:  Epilepsy Behav       Date:  2017-11-07       Impact factor: 2.937

4.  Novel biomarkers of metabolic dysfunction is autism spectrum disorder: potential for biological diagnostic markers.

Authors:  Asma M Khemakhem; Richard E Frye; Afaf El-Ansary; Laila Al-Ayadhi; Abir Ben Bacha
Journal:  Metab Brain Dis       Date:  2017-08-22       Impact factor: 3.584

5.  Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study.

Authors:  Sejal V Jain; Paul S Horn; Narong Simakajornboon; Dean W Beebe; Katherine Holland; Anna W Byars; Tracy A Glauser
Journal:  Sleep Med       Date:  2015-01-21       Impact factor: 3.492

6.  Evaluation of the role of chronic daily melatonin administration and pinealectomy on penicillin-induced focal epileptiform activity and spectral analysis of ECoG in rats: an in vivo electrophysiological study.

Authors:  Mehmet Yildirim; Selcen Aydin-Abidin; Ismail Abidin; Metehan Akca; Sinan Canpolat; Ali Cansu
Journal:  Neurochem Res       Date:  2013-05-14       Impact factor: 3.996

7.  GIRK Channels Mediate the Nonphotic Effects of Exogenous Melatonin.

Authors:  Lauren M Hablitz; Hylton E Molzof; Kathryn E Abrahamsson; Joanna M Cooper; Rebecca A Prosser; Karen L Gamble
Journal:  J Neurosci       Date:  2015-11-11       Impact factor: 6.167

8.  Homostachydrine is a Xenobiotic Substrate of OCTN1/SLC22A4 and Potentially Sensitizes Pentylenetetrazole-Induced Seizures in Mice.

Authors:  Misa Nishiyama; Noritaka Nakamichi; Tomoyuki Yoshimura; Yusuke Masuo; Tomoe Komori; Takahiro Ishimoto; Jun-Ichi Matsuo; Yukio Kato
Journal:  Neurochem Res       Date:  2020-08-26       Impact factor: 3.996

9.  Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures.

Authors:  Carlos Clayton Torres Aguiar; Anália Barbosa Almeida; Paulo Victor Pontes Araújo; Germana Silva Vasconcelos; Edna Maria Camelo Chaves; Otoni Cardoso do Vale; Danielle Silveira Macêdo; Luzia Kalyne Almeida Moreira Leal; Glauce Socorro de Barros Viana; Silvânia Maria Mendes Vasconcelos
Journal:  Cell Mol Neurobiol       Date:  2013-06-26       Impact factor: 5.046

Review 10.  Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models.

Authors:  Noemi Cardenas-Rodriguez; Bernardino Huerta-Gertrudis; Liliana Rivera-Espinosa; Hortencia Montesinos-Correa; Cindy Bandala; Liliana Carmona-Aparicio; Elvia Coballase-Urrutia
Journal:  Int J Mol Sci       Date:  2013-01-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.